Evidence map›Paper›PMID 41806275›Full record

Observational studyAdvances in therapy2026

Screening for Pulmonary Hypertension in Interstitial Lung Disease: Preliminary Results from the PHINDER Study.

David Zisman, Sandeep Sahay, Debabrata Bandyopadhyay, Amro Al-Astal, Meredith Broderick, Danielle Caudell Stamper, Hunter Champion, Maral DerSarkissian, Matthew Hunsucker, Dasom Lee and 11 more

Registry-linked trialAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05776225 (Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05776225 completednot on this map

Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection (PHINDER)

TypeobservationalSponsorUnited TherapeuticsRan2023 to 2026Enrolled314ConditionsInterstitial Lung Disease, Pulmonary HypertensionArmsRight heart catheterization (RHC)
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

David ZismanDivision of Pulmonary Medicine, Cleveland Clinic Florida, 3100 Weston Rd., Weston, FL, 33331, USA. zismand@ccf.org.
Sandeep SahayDivision of Pulmonary, Critical Care and Sleep Medicine, Houston Methodist Hospital, Houston, TX, USA.
Debabrata BandyopadhyayCenter for Advanced Lung Disease and Lung Transplant Program, Tampa General Hospital, Tampa, FL, USA.
Amro Al-AstalInternal Medicine and Pulmonology, Marshall University Joan C. Edwards School of Medicine, Huntington, WV, USA.
Meredith BroderickUnited Therapeutics Corporation, Research Triangle Park, Raleigh, NC, USA.
Danielle Caudell StamperMedpace, Cincinnati, OH, USA.
Hunter ChampionSoutheastern Cardiology, Columbus, GA, USA.
Maral DerSarkissianAnalysis Group, Los Angeles, CA, USA.
Matthew HunsuckerPulmonary and Critical Care Medicine, LeBauer Healthcare, Greensboro, NC, USA.
Dasom LeeUnited Therapeutics Corporation, Research Triangle Park, Raleigh, NC, USA.
Kevin MaherUnited Therapeutics Corporation, Research Triangle Park, Raleigh, NC, USA.
Andrew NelsenUnited Therapeutics Corporation, Research Triangle Park, Raleigh, NC, USA.
Raj ParikhDepartment of Pulmonary Critical Care Medicine, Hartford Hospital, Hartford, CT, USA.
Franck RahaghiUnited Therapeutics Corporation, Research Triangle Park, Raleigh, NC, USA.
Abhijit RavalInternal Medicine, Pulmonary Disease & Critical Care, AnMed Pulmonary And Sleep Medicine, Anderson, SC, USA.
Claire M ThrasherUnited Therapeutics Corporation, Research Triangle Park, Raleigh, NC, USA.
Tejaswini KulkarniDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Oksana A ShlobinAdvanced Lung Disease and Transplant Program, Inova Schar Heart and Vascular Institute, Inova Fairfax Hospital, Falls Church, VA, USA.
David G KielyDivision of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, NIHR Biomedical Research Centre, Sheffield, UK.
Steven NathanAdvanced Lung Disease and Transplant Program, Inova Schar Heart and Vascular Institute, Inova Fairfax Hospital, Falls Church, VA, USA.
Mary Beth ScholandDepartment of Medicine, University of Utah, Salt Lake City, UT, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionInterstitial lung disease (ILD) is frequently complicated by pulmonary hypertension (PH) resulting in reduced functional capacity, diminished quality of life, and increased mortality. However, standardized screening for PH in ILD is lacking, causing delays in diagnosis and treatment. PHINDER (NCT05776225) is a prospective multicenter study that aims to identify parameters for the detection of PH in ILD.

methodsData were collected prospectively in patients with ILD from predefined routine testing, including clinical, physiological, and imaging assessments. Precapillary PH was defined as mean pulmonary arterial pressure > 20 mmHg, pulmonary artery wedge pressure ≤ 15 mmHg, and pulmonary vascular resistance (PVR) > 2 Wood units (WU). Investigators estimated probability of precapillary PH based on noninvasive evaluations before confirmation by right heart catheterization (RHC).

resultsPreliminary results included 190 participants; 105 (55%) had precapillary PH and 26 (14%) had severe PH (PVR > 5 WU). Notable parameters associated with precapillary PH included supplemental oxygen use (OR 3.6, p = 0.004), diffusing capacity of the lung for carbon monoxide ([DLCO] OR 0.9, p = 0.005), forced vital capacity % to DLCO % ratio (OR 1.1, p = 0.008), tricuspid annular plane systolic excursion to right ventricular systolic pressure ratio (OR 0.8, p = 0.020), tricuspid regurgitant velocity (OR 4.4, p = 0.006), pulmonary artery (PA) enlargement (OR 10.6, p < 0.001), PA/aorta diameter ratio (OR 1.7, p = 0.004), and right to left ventricle diameter ratio (OR 1.5, p = 0.021). There was a trend toward higher likelihood of PH with higher clinician suspicion of PH before RHC, but gestalt-based assessment showed limited accuracy relative to hemodynamic confirmation (positive predictive value, 59%; negative predictive value, 68%; accuracy, 60%).

conclusionsPreliminary findings support the composite use of pulmonary function testing, lung imaging, and echocardiography to improve early detection of precapillary PH in ILD and guide structured screening strategies. The final data set from PHINDER will provide guidance on thresholds for continuous variables with application in diagnosing PH in ILD, facilitating the development of a validated evidence-based screening tool to aid the detection of PH in ILD. TRAIL REGISTRATION: NCT05776225.

Indexed as

Hypertension, PulmonaryLung Diseases, InterstitialAgedCardiac CatheterizationEchocardiographyFemaleHumansMaleMiddle AgedProspective StudiesPulmonary Wedge PressureVascular ResistanceDetectionEchocardiographyLung imagingRight heart catheterization

Identifiers

PMID41806275
PMCPMC13156216

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.